SVRA Stock Has a $150M FDA Catalyst Incoming
Savara (SVRA) stock analysis: +198% upside target ahead of FDA decision — buy or sell?
👉 Want this level of research on ANY COMPANY IN THE WORLD... for FREE? Check us out at: https://flash.stocksentinel.ai/?utm_source=rss_podcast&utm_medium=podcast&utm_campaign=freja_and_friends
In this deep dive, we break down Savara Inc. (SVRA) and its lead candidate MOLBREEVI ahead of the pivotal November 22, 2026 FDA PDUFA decision. With a probability-weighted price target of $14.59 representing +197.8% upside alongside $173M in cash and $150M in contingent non-dilutive capital, the key question for…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.